eMedicine World Medical Library

Excerpt from Traumatic Optic Neuropathy


Synonyms, Key Words, and Related Terms: traumatic optic neuropathy, optic neuropathy, optic nerve injury, vision loss, trauma, frontal trauma, orbital trauma, optic nerve avulsion, optic nerve transection, diffuse orbital hemorrhage, localized orbital hemorrhage, optic nerve sheath hematoma, orbital emphysema, TON

Please click here to view the full topic text: Traumatic Optic Neuropathy

Traumatic optic neuropathy (TON) refers to an acute injury of the optic nerve secondary to trauma. The optic nerve axons may be damaged either directly or indirectly and the visual loss may be partial or complete. An indirect injury to the optic nerve typically occurs from the transmission of forces to the optic canal from blunt head trauma. This is in contrast to direct TON, which results from an anatomical disruption of the optic nerve fibers from penetrating orbital trauma, bone fragments within the optic canal, or nerve sheath hematomas. 

Problem

Patients with TON can present with a variable degree of vision loss (decreased visual acuity, visual field abnormalities, or loss of color vision). Most cases (up to 60%) present with severe vision loss of light perception (LP) or worse. In the acute phase, the optic nerve usually appears normal on funduscopic examination, but optic nerve atrophy is often seen 3-6 weeks after the injury.

Frequency

The incidence of TON in the setting of a closed traumatic head injury in various studies ranges from 0.5-5%. The vast majority of TON cases are seen in males (up to 85%), with a mean age of 34 years. Motor vehicle and bicycle accidents account for the majority of causes, followed by falls and assaults. TON has also been associated with penetrating orbital trauma (eg, stab wounds, pellet and gunshot wounds, foreign bodies) and recreational sports (eg, paint ball injury).   

Pathophysiology

The pathophysiology of TON is thought to be multifactorial, and some researchers have also postulated a primary and secondary mechanism of injury. In indirect TON cases, the injury to the axons is thought to be induced by shearing forces that are transmitted to the fibers or to the vascular supply of the nerve. Studies have shown that forces applied to the frontal bone and malar eminences are transferred and concentrated in the area near the optic canal. The tight adherence of the optic nerve’s dural sheath to the periosteum within the optic canal is also thought to contribute to this segment of the nerve being extremely susceptible to the deformative stresses of the skull bones. Such injury leads to ischemic injury to the retinal ganglion cells within the optic canal.

A secondary mechanism can result in optic nerve swelling after the occurrence the acute injury. The optic nerve swelling can exacerbate retinal ganglion cell degeneration by further compromising the vascular blood supply, either through a rise in intraluminal pressure or reactive vasospasm. These secondary mechanisms, in theory, form the rationale for optic canal decompression via medical (ie, steroids) or surgical means (ie, bony decompression). Finally, the intracranial segment of the optic nerve may be damaged by forces delivered to the axons by the shifting of the brain following head trauma. With this mechanism, the nerve fibers may be injured against the falciform dural fold or through a shearing force where the nerve becomes fixed as it enters the intracranial opening of the optic foramen.

Please click here to view the full topic text: Traumatic Optic Neuropathy

About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers
Labelled with ICRA © 1996-2006 by WebMD.
All Rights Reserved.

Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER